Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.63 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2829293 | 0.89 | GRM5 (0.74) | GRM5KMT2A | |
| SCHEMBL2827810 | 0.79 | GRM5 (0.41) | GRM5NPC1RAB9AKMT2A | |
| SCHEMBL2827669 | 0.78 | GRM5 (0.65) | GRM5PDE10A | |
| SCHEMBL5184044 | 0.76 | GRM5 (0.68) | GRM5PDE10ANPC1RAB9A | |
| SCHEMBL5198047 | 0.75 | GRM5 (0.64) | GRM5PDE10ANPC1RAB9A | |
| SCHEMBL2828771 | 0.71 | GRM5 (0.55) | GRM5NPC1RAB9AKMT2A | |
| SCHEMBL2824622 | 0.71 | GRM5 (0.59) | GRM5PDE10ANPC1RAB9A | |
| SCHEMBL2829463 | 0.71 | GRM5 (0.54) | GRM5NPC1RAB9AKMT2A | |
| SCHEMBL2825932 | 0.69 | GRM5 (0.79) | GRM5 | |
| SCHEMBL2846654 | 0.69 | GRM5 (1.00) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844044-B1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-07-21 | — | — | EP | disclosed |
| US-7678815-B2 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1844044-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006074884-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | GRM1, GRM2, GRIA4 | GRM5 4/4885PDE10A 1697/4885NPC1 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.